The 2025 Department of Defense Tenant Satisfaction Housing Survey will launch and be available to Fort Gregg-Adams residents ...
VIENNA, Va., February 20, 2025--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial. VIENNA, Va., February 18, 2025--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows ...
Shaun Magher, creative director and animation director of thirty years’ experience, and now Course Director for BA Digital ...
Vor Biopharma's trem-cel offers hope for AML treatment, but financial risks and early-stage progress suggest caution. Learn ...
--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it is in the final stages for the launch of its 212-patient Confirmatory Registration Study for Multikine* (Leukocyte ...
Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...